الفهرس | Only 14 pages are availabe for public view |
Abstract The presence of prostate cancer or male breast cancer is an absolute contraindication to testosterone replacement. Risks of testosterone therapy include: erythropoiesis, gynaecomastia, exacerbation or development of sleep apnea and Formulation-specific adverse effects such as hepatotoxicity with oral methyltestosterone. Monitoring of men receiving testosterone therapy should include: evaluation of symptoms, any adverse effects, testosterone levels, hematocrit, bone mineral density and PSA. |